Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Donor Eligibility Criteria:~* Age 18-60~* A history of a positive nasopharyngeal swab for COVID-19 or a history of positive titer test.~* At least 14 days from resolution of COVID-19-associated symptoms including fevers~* One negative nasopharyngeal swabs for COVID-19 RNA~* Covid-19 neutralizing antibody \>1:64~* Adequate venous access for apheresis~* Meets donor eligibility criteria in accordance to Hackensack University Medical Center (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at the JTCC, and all regulatory agencies as describes in SOP 800 01 (Appendix A)~* Required testing of the donor and product must be performed in accordance to FDA regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)~Recipient Eligibility Criteria:~Recipients age \>18 years old, are assigned to one of two clinical tracks, track 2 or 3, based on COVID-19 disease severity. Onset of first symptoms \< 9 days.~Track 2:~* Hospitalized, moderate symptoms requiring medical care for COVID-19 infection~* Symptoms may include fever, dyspnea, dehydration among others~* Hypoxemia may be present but is not a requirement~Track 3:~* Requiring mechanical ventilation for the care of COVID-19 infection~* Requiring non-invasive positive pressure ventilation (NIPPV), such as continuous airway pressure (CPAP),bi-level positive airway pressure (BiPAP) or high flow nasal canula (HFNC).~Recipient exclusion criteria:~* History of severe transfusion reaction to plasma products~* Infusion of immune globulin within the previous 30 days~* AST or ALT \> 10 x upper limit of normal~* Requirement for vasopressors~* COVID-19-associated acute kidney injury requiring dialysis~* DNR status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): Fresh or frozen plasma will be infused one time to patients

Based on this trial design, predict the completion outcome and termination type (if applicable).